MAPK3 and neoplasm: In this new therapeutic scenario, targeted inhibition of the ERK1/2 pathway, which is hyperactive in at least 40% of cancers and plays a pivotal role in tumor cell proliferation and metastasis, is an established strategy in various tumors [32].